Co-Diagnostics, Inc. (CODX)
| Previous close | 1.1400 |
| Open | 1.1500 |
| Bid | 0.8280 x 200 |
| Ask | 1.4400 x 200 |
| Day's range | 1.1100 - 1.1799 |
| 52-week range | 0.9750 - 1.8900 |
| Volume | |
| Avg. volume | 56,052 |
| Market cap | 34.698M |
| Beta (5Y monthly) | -0.68 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.2000 |
| Earnings date | 09 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 2.50 |
PR NewswireCo-Diagnostics, Inc. Announces First Quarter 2024 Earnings Release Date and Webcast
Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its first quarter 2024 financial results on Thursday, May 9, 2024, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts and institutional investors. Management on the call will include Dwight Egan, Chief Exec
- PR Newswire
Co-Diagnostics, Inc. to Host Booth and Deliver Presentation at APRC 2024 in Taiwan
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company will be hosting a booth and delivering a presentation at the 9th Asia Pacific Region Conference (APRC) of the International Union Against Tuberculosis and Lung Disease on April 26-29, 2024 in Taipei, Taiwan.
PR NewswireCo-Diagnostics, Inc. Inaugurates New Manufacturing Facility in Utah with Ribbon Cutting Event
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it held the ribbon cutting event for its new manufacturing facility yesterday in the City of South Salt Lake. The facility has been designed to manufacture the Co-Dx Pro™ instrument and test cups for the new platform*, as well as the Company's patented Co-Primers™ chemistry that underpins the Compa
